Announcement • Apr 25
Anhui Huaren Health Pharmaceutical Co., Ltd., Annual General Meeting, May 18, 2026 Anhui Huaren Health Pharmaceutical Co., Ltd., Annual General Meeting, May 18, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China Reported Earnings • Apr 25
First quarter 2026 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.20 (up from CN¥0.15 in 1Q 2025). Revenue: CN¥1.42b (up 12% from 1Q 2025). Net income: CN¥79.3m (up 30% from 1Q 2025). Profit margin: 5.6% (up from 4.8% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥20.43, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 42x in the Consumer Retailing industry in China. Total returns to shareholders of 5.4% over the past three years. Announcement • Mar 31
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥25.08, the stock trades at a trailing P/E ratio of 53.8x. Average trailing P/E is 54x in the Consumer Retailing industry in China. Total returns to shareholders of 134% over the past year. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥22.17, the stock trades at a trailing P/E ratio of 47.6x. Average trailing P/E is 49x in the Consumer Retailing industry in China. Total returns to shareholders of 116% over the past year. Announcement • Dec 31
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026 Valuation Update With 7 Day Price Move • Dec 17
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥18.20, the stock trades at a trailing P/E ratio of 39x. Average trailing P/E is 52x in the Consumer Retailing industry in China. Total returns to shareholders of 49% over the past year. New Risk • Nov 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Nov 26
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥17.40, the stock trades at a trailing P/E ratio of 37.3x. Average trailing P/E is 48x in the Consumer Retailing industry in China. Total returns to shareholders of 46% over the past year. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥16.04, the stock trades at a trailing P/E ratio of 34.4x. Average trailing P/E is 50x in the Consumer Retailing industry in China. Total returns to shareholders of 17% over the past year. Reported Earnings • Oct 25
Third quarter 2025 earnings released: EPS: CN¥0.13 (vs CN¥0.087 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.13 (up from CN¥0.087 in 3Q 2024). Revenue: CN¥1.39b (up 26% from 3Q 2024). Net income: CN¥53.0m (up 52% from 3Q 2024). Profit margin: 3.8% (up from 3.2% in 3Q 2024). The increase in margin was driven by higher revenue. Announcement • Sep 30
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025 Reported Earnings • Sep 01
Second quarter 2025 earnings released: EPS: CN¥0.11 (vs CN¥0.063 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.11 (up from CN¥0.063 in 2Q 2024). Revenue: CN¥1.24b (up 16% from 2Q 2024). Net income: CN¥42.5m (up 69% from 2Q 2024). Profit margin: 3.4% (up from 2.4% in 2Q 2024). The increase in margin was driven by higher revenue. Announcement • Jul 02
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 27, 2025 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 27, 2025 New Risk • Jun 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Jun 27
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to CN¥14.54, the stock trades at a trailing P/E ratio of 38.5x. Average trailing P/E is 32x in the Consumer Retailing industry in China. Total returns to shareholders of 43% over the past year. Declared Dividend • Jun 20
Dividend of CN¥0.10 announced Dividend of CN¥0.10 is the same as last year. Ex-date: 25th June 2025 Payment date: 25th June 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (27% earnings payout ratio) and cash flows (6% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 19% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • May 23
Anhui Huaren Health Pharmaceutical Co., Ltd. (SZSE:301408) agreed to acquire an unknown majority stake in Fujian Yangzu Huimin Medicine Chain Co., Ltd, Fujian Haihua Pharmaceutical Chain Co., Ltd. and Tonglu Yishengtang Pharmacy Chain Co., Ltd. from Ningbo Minzhehui Investment Partnership Enterprise (Limited Partnership). Anhui Huaren Health Pharmaceutical Co., Ltd. (SZSE:301408) agreed to acquire an unknown majority stake in Fujian Yangzu Huimin Medicine Chain Co., Ltd, Fujian Haihua Pharmaceutical Chain Co., Ltd. and Tonglu Yishengtang Pharmacy Chain Co., Ltd. from Ningbo Minzhehui Investment Partnership Enterprise (Limited Partnership) on May 19, 2025. The Company agreed to purchase 46.01% equity in Fujian Yangzu Huimin Medicine Chain Co., Ltd. for CNY 133.429 million, 46.01% equity in Fujian Haihua Pharmaceutical Chain Co., Ltd. for CNY 125.1472 million, and 70.01% equity in Tonglu Yishengtang Pharmacy Chain Co., Ltd. for CNY 68.25975 million, all held by Ningbo Minzhehui Investment Partnership Enterprise (Limited Partnership). Upon the completions of these acquisitions, the Company will hold a 51% stake in Fujian Yangzu Huimin Medicine Chain Co., Ltd, a 54.557% stake in Fujian Haihua Pharmaceutical Chain Co., Ltd, and a 100% stake in Tonglu Yishengtang Pharmacy Chain Co., Ltd. The Company plans to use its own funds and change the purpose of some raised funds for payment. If the review for changing the purpose of raised funds is not approved, the company will use its own funds entirely. The Board of Directors authorized the management to handle the relevant procedures for this transaction, including but not limited to signing transaction documents and handling industrial and commercial registration changes.
Anhui Huaren Health Pharmaceutical Co., Ltd. held its 9th meeting of the 5th Board of Directors, where the “Proposal on the Acquisition of Equity in Three Pharmaceutical Chain Companies in Fujian and Zhejiang” was reviewed and approved. Announcement • May 22
Anhui Huaren Health Pharmaceutical Co., Ltd. Approves Cash Dividend for 2024 Anhui Huaren Health Pharmaceutical Co., Ltd. at its Annual General Meeting of 2024 on 16 May 2025 approved: Cash dividend/10 shares (tax included): CNY 1.00000000 for 2024. Reported Earnings • Apr 25
Full year 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.29 in FY 2023) Full year 2024 results: EPS: CN¥0.34 (up from CN¥0.29 in FY 2023). Revenue: CN¥4.53b (up 19% from FY 2023). Net income: CN¥137.7m (up 20% from FY 2023). Profit margin: 3.0% (in line with FY 2023). Announcement • Apr 25
Anhui Huaren Health Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2025 Anhui Huaren Health Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (304% cash payout ratio). Share price has been volatile over the past 3 months (8.2% average weekly change). Profit margins are more than 30% lower than last year (3.1% net profit margin). Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥10.20, the stock trades at a trailing P/E ratio of 30.3x. Average trailing P/E is 30x in the Consumer Retailing industry in China. Total loss to shareholders of 12% over the past year. Announcement • Mar 31
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥13.54, the stock trades at a trailing P/E ratio of 40.2x. Average trailing P/E is 26x in the Consumer Retailing industry in China. Total returns to shareholders of 23% over the past year. Announcement • Dec 31
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.087 (vs CN¥0.074 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.087 (up from CN¥0.074 in 3Q 2023). Revenue: CN¥1.10b (up 16% from 3Q 2023). Net income: CN¥35.0m (up 17% from 3Q 2023). Profit margin: 3.2% (up from 3.1% in 3Q 2023). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥11.28, the stock trades at a trailing P/E ratio of 34.9x. Average trailing P/E is 26x in the Consumer Retailing industry in China. Total loss to shareholders of 35% over the past year. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Share price has been volatile over the past 3 months (7.4% average weekly change). Profit margins are more than 30% lower than last year (3.1% net profit margin). Announcement • Sep 30
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to CN¥12.35, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 27x in the Consumer Retailing industry in China. Total loss to shareholders of 32% over the past year. Buy Or Sell Opportunity • Sep 27
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 5.5% to CN¥10.79. The fair value is estimated to be CN¥8.80, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last year. Earnings per share has declined by 35%. Buy Or Sell Opportunity • Sep 04
Now 22% overvalued Over the last 90 days, the stock has fallen 1.9% to CN¥10.66. The fair value is estimated to be CN¥8.73, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last year. Earnings per share has declined by 35%. Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.063 (vs CN¥0.072 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.063 (down from CN¥0.072 in 2Q 2023). Revenue: CN¥1.06b (up 20% from 2Q 2023). Net income: CN¥25.2m (down 12% from 2Q 2023). Profit margin: 2.4% (down from 3.2% in 2Q 2023). The decrease in margin was driven by higher expenses. Announcement • Jun 29
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Announcement • Jun 08
Anhui Huaren Health Pharmaceutical Co., Ltd. Announces Dividend Implementation for 2023, Payable on 17 June 2024 Anhui Huaren Health Pharmaceutical Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 1.00000000; Record date: 14 June 2024; Ex-date: 17 June 2024; Payment date: 17 June 2024. Announcement • Apr 30
Anhui Huaren Health Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024 Anhui Huaren Health Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥10.19, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 29x in the Consumer Retailing industry in China. Total loss to shareholders of 47% over the past year. Announcement • Mar 30
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024 Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥12.45, the stock trades at a trailing P/E ratio of 27.6x. Average trailing P/E is 27x in the Consumer Retailing industry in China. Announcement • Dec 30
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Apr 29, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.074 (vs CN¥0.24 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.074 (down from CN¥0.24 in 3Q 2022). Revenue: CN¥947.3m (up 2.3% from 3Q 2022). Net income: CN¥29.8m (down 63% from 3Q 2022). Profit margin: 3.1% (down from 8.7% in 3Q 2022). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 25
Second quarter 2023 earnings released Second quarter 2023 results: EPS: CN¥0.072. Net income: CN¥28.8m (up CN¥28.8m from 2Q 2022). New Risk • Aug 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥19.79, the stock trades at a trailing P/E ratio of 45.3x. Average trailing P/E is 32x in the Consumer Retailing industry in China. Announcement • Jul 01
Anhui Huaren Health Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023 Anhui Huaren Health Pharmaceutical Co., Ltd. announced that they will report first half, 2023 results on Aug 25, 2023 Reported Earnings • Apr 14
Full year 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.21 in FY 2021) Full year 2022 results: EPS: CN¥0.47 (up from CN¥0.21 in FY 2021). Revenue: CN¥3.26b (up 40% from FY 2021). Net income: CN¥161.4m (up 131% from FY 2021). Profit margin: 4.9% (up from 3.0% in FY 2021). The increase in margin was driven by higher revenue. 
